ScreenerHero

EDSA Edesa Biotech, Inc.

NAS · US · Healthcare · Biotechnology · edesabiotech.com
3.895USD+4.70%Mkt Cap: 52.63M $P/E: —

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It dev…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap52.63M USD
Enterprise Value33.94M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-7.19M USD
Revenue/Share—
Last Price3.895 USD
Fiscal Year EndSep 2025
MR QuarterJun 2026
Employees17
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.93
PEG—
EV/EBITDA-2.34
EV/Revenue—
P/S—
P/B90.73
EPS (TTM)-1.65
EPS (Forward)-1.93
52W Range
0.720016% of range20.32
52W High20.32 USD
52W Low0.7200 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-57.71%
ROA-53.11%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.32M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-7.63%
Net Debt-10.33M USD
Net Debt/EBITDA0.71
Balance Sheet
Debt/Equity0.00
Current Ratio2.76
Quick Ratio2.70
Book Value/Sh0.04 USD
Cash/Share1.07 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJun 10, 2019
Splits
Last Split1:7
Split DateOct 11, 2023
Analyst Consensus
Rating—
Target (Mean)16.33 USD
Upside (mean)+319.3%
Target Range9.000 USD – 21.00 USD
9.000+319.3% to mean21.00
# Analysts3
Ownership
Shares Out.13.51M
Float7.19M
Insiders13.50%
Institutions37.44%
Short Interest
Short Ratio2.5d
Short % Float1.71%
Short % Out.1.62%
Shares Short218.77K
Short (prev mo.)208.96K
Technical
SMA 504.651 (-16.3%)
SMA 2005.531 (-29.6%)
Beta1.22
S&P 52W Chg16.45%
Avg Vol (30d)64.62K
Avg Vol (10d)35.12K
Technical Indicators
RSI (14)42.1
MACD-0.2958
MACD Signal-0.3334
MACD Hist.+0.0376
BB Upper4.720 USD
BB Middle4.074 USD
BB Lower3.429 USD
BB Width31.69%
ATR (14)0.3663 USD
Vol Ratio (20d)0.51x